Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: A prognostic factor in a large breast cancer cohort

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2641-2650

  Levesque, Michael A ^a   Yu, He ^a   Clark, Gary M ^a   Diamandis, Eleftherios P ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031927693     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2641     Document Type: Article

References (50)

1. McGuire WL: Guidelines for evaluating new prognostic factors. J Natl Cancer Inst 83:154-155, 1991
2. Thor AD, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
3. Friedrichs K, Gluba S, Eidtmann H, et al: Overexpression of p53 and prognosis in breast cancer. Cancer 72:3641-3647, 1993
4. Silvestrini R, Benini E, Daidone MG, et al: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
5. Pietilainen T, Lipponen P, Aaltomaa S, et al: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177:225-232, 1995
6. Rosen PP, Lesser ML, Arroyo CD, et al: p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13:821-830, 1995
7. Sjogren S, Inganas M, Norberg T, et al: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996
8. Nigro JM, Baker JS, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:105-108, 1989
9. Runnebaum IB, Nagarajan M, Bowman M, et al: Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A 88:10657-10661, 1991
10. Sommer SS, Cunningham J, McGovern RM, et al: Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States. J Natl Cancer Inst 84:246-252, 1992
11. Shiao Y-H, Chen VW, Scheer WD, et al: Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55:1485-1490, 1995
12. Kastan MB, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-597, 1992
13. Lowe SW, Schmitt EM, Smith SW, et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
14. Lee S, Elenbaas B, Levine A, et al: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-1020, 1995
15. Eyfjord JE, Thorlacius S, Steinarsdottir M, et al: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646-651, 1995
16. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
17. Elledge RM, Gray R, Mansour E, et al: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
18. Martinazzi M, Crivelli F, Zampatti C, et al: Relationship between p53 expression and other prognostic factors in human breast carcinoma. Am J Clin Pathol 100:213-217, 1993
19. Lipponen P, Ji H, Aaltomaa S, et al: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55:51-56, 1993
20. Wynford-Thomas D: p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 166:329-330, 1992
21. Bartkova J, Bartek J, Vojtesek B, et al: Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumors. Eur J Cancer 29A:881-886, 1993
22. Borg A, Lennerstrand J, Stenmark-Askmalm M, et al: Prognostic significance of p53 overexpression in primary breast cancer: A novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71:1013-1017, 1995
23. de Witte HH, Koekens JA, Lennerstrand J, et al: Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69:125-130, 1996
24. Dressier LG, Seamer LC, Owens MA, et al: DNA flow cytometry and prognostic factors in 1131 frozen breast cancer specimens. Cancer 61:420-427, 1988
25. Clark GM, Dressier LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
26. Scatchard G: The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 51:660-672, 1949
27. Lowry OH, Roseborough NJ, Farr AL, et al: Protein measurement with folin-phenol reagent. J Biol Chem 193:265-275, 1951
28. Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3:157-163, 1983
29. Clark GM, McGuire WL, Hubay CA, et al: Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 309:1343-1347, 1983
30. Levesque MA, D'Costa M, Angelopoulou K, et al: Time-resolved immunofluorometric assay of p53. Clin Chem 41:1720-1729, 1995
31. Christopoulos TK, Diamandis EP: Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 64:342-346, 1992
32. Vojtesek B, Bartek J, Midgley CA, et al: An immunochemical analysis of human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244, 1992
33. Cox DR: Regression models and life tables. J R Stat Soc (B) 34:187-202, 1972
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
35. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
36. Caleffi M, Teague MW, Jensen RA, et al: p53 gene mutations and steroid receptor status in breast cancer. Cancer 73:2147-2156, 1994
37. Vojtesek B, Fisher CJ, Barnes DM, et al: Comparison between p53 staining in tissue sections and p53 protein levels measured by an ELISA technique. Br J Cancer 67:1254-1258, 1993
38. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunocytochemistry? - Revisited! J Pathol 172:1-4, 1994
39. Kovach JS, Hartmann A, Blaszyk H, et al: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A 93:1093-1096, 1996
40. Charpin C, Garcia S, Bouvier C, et al: Quantitative immunocytochemical assays on frozen sections of p53: Correlation to the follow-up of patients with breast carcinomas. Am J Clin Pathol 106:640-646, 1996
41. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" outpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-834, 1994
42. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
43. Silvestrini R, Daidone MG, Benini E, et al: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 2:2007-2013, 1996
44. Silvestrini R, Benini E, Veneroni S, et al: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
45. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
46. Aas T, Borresen AL, Geisler S, et al: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2:811-813, 1996
47. Makris A, Powles TJ, Dowsett M, et al: p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345:1181-1182, 1995
48. Barbareschi M, Doglioni C, Veronese S, et al: p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. Eur J Cancer 32A:2182-2183, 1996
49. Jansson T, Inganas M, Sjogren S, et al: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751, 1995
50. Bergh J, Norberg T, Sjogren S, et al: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1:1029-1034, 1995